Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 1034Neoplasms 815Carcinoma, Non-Small-Cell Lung 799Prostatic Neoplasms 621Colorectal Neoplasms 529Lung Neoplasms 486Neoplasm Metastasis 434Multiple Myeloma 395Leukemia, Myeloid, Acute 391Ovarian Neoplasms 334Pancreatic Neoplasms 316Melanoma 297Squamous Cell Carcinoma of Head and Neck 268Recurrence 256Carcinoma, Hepatocellular 250Glioblastoma 238Brain Neoplasms 237Triple Negative Breast Neoplasms 213Carcinoma, Renal Cell 209Head and Neck Neoplasms 208Precursor Cell Lymphoblastic Leukemia-Lymphoma 201Lymphoma 201Stomach Neoplasms 197Endometrial Neoplasms 189Uterine Cervical Neoplasms 185Lymphoma, Non-Hodgkin 180Glioma 180Sarcoma 179Lymphoma, Large B-Cell, Diffuse 167Hematologic Neoplasms 162

Interventions

Taxes 1Standard of Care 1Panitumumab 1Pancreaticoduodenectomy 1Optical Imaging 1Losartan 1Gemcitabine 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Pancreatic Adenocarcinoma × 90 days × Clear all
NCT07619391 2026-06-02

MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
30 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT07547033 2026-04-23

EQUINOXE

Assistance Publique - Hôpitaux de Paris

Phase NA Not yet recruiting
150 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡